SC
BEAM icon

Stephens Consulting’s Beam Therapeutics BEAM Stock Holding History

Stephens Consulting’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$586 – 1295
2025
Q1 		$586 Buy
+30
New +$786 ﹤0.01% 890

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Stephens Consulting's BEAM Position: Q2 2025 in Review

Stephens Consulting sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 30 shares — an estimated $586 sold.

Stephens Consulting first reported a position in BEAM in Q1 2025 and held it in 1 quarter. The position peaked at $586 in Q1 2025. 216 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Stephens Consulting reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 30 Beam Therapeutics shares in Q2 2025, an estimated $586.
  • Stephens Consulting first reported a position in Beam Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Beam Therapeutics position peaked at $586 in Q1 2025.
  • 216 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.